Discussions

As an industry-leading expert in the field of neurological disease research, Creative Biolabs has accumulated extensive experience from practice. We have established an advanced platform to provide our customers with a variety of cell culture models to meet the needs of neuroscience research.

As the leading custom service provider, Creative Biolabs has been keeping a close eye on the development of the epidemic situation and accelerating the development of detection kits. Creative Biolabs provides Monkeypox virus nucleic acid detection kits and ELISA kits.

Nucleic acid amplification testing (NAAT), which looks for specific viral DNA sequences using real-time or conventional polymerase chain reactions ( PCR), is used to confirm MPXV infection. Sequencing can be done alone or in conjunction with PCR.

With years of experience, Creative Biolabs can offer an extensive range of recombinant proteins and peptides including orthopoxviruses family, parapoxviruses family, molluscipoxviruses family, yatapoxviruses family, capripoxviruses family, suipoxviruses family, leporipoxviruses family and avipoxviruses family. Creative Biolabs is committed to providing highly customized comprehensive solutions with the best quality to advance your projects.

Creative Biolabs is the leading custom service provider that has extensive experience in various antibody production and engineering fields. As the leading custom service provider specializing in antibody production and engineering fields, Creative Biolabs has been keeping a close eye on the development of the epidemic situation and accelerating the development of monkeypox antibodies.

Creative Biolabs can offer you several creative approaches to generate TCRs that are specific for the antigens that are expressed by a wider variety of tumor cell types to meet your special needs and also has optimized strategies to increase TCR affinity.

Creative Biolabs offers the world leading custom TCR development service with the most advanced techniques and years of experiences to establish the solid platform for TCR production. Our technical experts are looking forward to designing a strategy of TCR biomarker identification & selection required for your assays and will be able to recommend an approach appropriate to your project needs.

Although clinical success has been achieved in a few tumor types, the types of surface proteins that can be targeted by this technology are limited, which severely limits the development of CAR-T cells for multiple tumor types. Besides, the targeted surface proteins so far are also expressed on normal cells, leading to CAR-T-mediated killing of non-cancer cells and potentially life-threatening side effects related to the intensity of the subsequent immune response.